We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
Read MoreHide Full Article
Key Takeaways
COO opened The Vision Centre in England to accelerate contact lens development and commercialization.
COO unveiled six advances across myopia control, SiHy, toric and multifocal lenses, with launches planned.
The Vision Centre combines R&D, clinical, manufacturing and commercial capabilities to speed innovation.
The Cooper Companies (COO - Free Report) recently announced the opening of The Vision Centre, a new global innovation hub in Southampton, England, for its CooperVision business, focused on accelerating contact lens development and commercialization. The company also unveiled six product advancements spanning myopia control, silicone hydrogel (SiHy), toric and multifocal contact lenses, with launches planned over the next several years.
Per management, innovation will continue to be a major driver of The Cooper Companies’ future growth. The company is strengthening its focus on high-potential opportunities by expanding innovation capabilities and bringing together advanced technologies and top talent. These efforts are expected to help CooperVision accelerate product launches, advance its scientific leadership and support sustainable long-term growth.
COO Stock Trend Following the News
Following the announcement, COO stock gained 1.4% at yesterday’s close. Year to date, shares of the company have declined 31.6% against the industry’s 2.8% growth and the S&P 500’s 12% gain.
The new innovation hub and accelerated pipeline development should support The Cooper Companies’ efforts to drive organic growth through CooperVision. Investments in myopia control, SiHy materials, toric and multifocal lenses may help the company address evolving patient needs, broaden its product portfolio and create additional opportunities in the global contact lens market.
COO currently has a market capitalization of $10.51 billion.
Image Source: Zacks Investment Research
More on CooperVision’s Innovation Strategy
The Vision Centre is designed to bring research and development, clinical expertise, pilot manufacturing, advanced technologies and commercial capabilities under one facility. The hub will support research, clinical studies, product development and new product introduction programs, while enabling greater collaboration across the innovation lifecycle.
CooperVision’s accelerated pipeline development program includes a complete family of 1-day contact lenses for myopia control, a premium 1-day SiHy technology and a next-generation SiHy material for monthly contact lenses. COO is also developing a 1-day SiHy product aimed at expanding fits, a 1-day SiHy toric multifocal lens and a new toric 1-day lens experience for patients with astigmatism.
The Vision Centre builds on CooperVision’s expertise in silicon hydrogel materials, toric and multifocal designs and myopia control. The company’s products currently reach more than 40 million people worldwide. The facility will also use digital tools, data science, analytics and emerging AI-enabled capabilities to improve product development and accelerate the transition from scientific insights to commercial solutions.
The investment comes as The Cooper Companies continues to focus on CooperVision’s commercial execution, operational excellence and innovation. The company expects to provide further updates on its product pipeline going forward and remains focused on opportunities to enhance revenue growth, expand profitability and increase shareholder value.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global soft contact lenses market is estimated to reach $11.3 billion in 2026 and is projected to witness a CAGR of 8.1% through 2030.
Factors such as the rising prevalence of vision-related disorders, including myopia, presbyopia and astigmatism, increasing preference for daily disposable lenses, advancements in silicone hydrogel materials and growing demand for comfortable and convenient vision-correction options are supporting market growth.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
View the Zacks #1 Rank List
Image: Bigstock
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
Key Takeaways
The Cooper Companies (COO - Free Report) recently announced the opening of The Vision Centre, a new global innovation hub in Southampton, England, for its CooperVision business, focused on accelerating contact lens development and commercialization. The company also unveiled six product advancements spanning myopia control, silicone hydrogel (SiHy), toric and multifocal contact lenses, with launches planned over the next several years.
Per management, innovation will continue to be a major driver of The Cooper Companies’ future growth. The company is strengthening its focus on high-potential opportunities by expanding innovation capabilities and bringing together advanced technologies and top talent. These efforts are expected to help CooperVision accelerate product launches, advance its scientific leadership and support sustainable long-term growth.
COO Stock Trend Following the News
Following the announcement, COO stock gained 1.4% at yesterday’s close. Year to date, shares of the company have declined 31.6% against the industry’s 2.8% growth and the S&P 500’s 12% gain.
The new innovation hub and accelerated pipeline development should support The Cooper Companies’ efforts to drive organic growth through CooperVision. Investments in myopia control, SiHy materials, toric and multifocal lenses may help the company address evolving patient needs, broaden its product portfolio and create additional opportunities in the global contact lens market.
COO currently has a market capitalization of $10.51 billion.
Image Source: Zacks Investment Research
More on CooperVision’s Innovation Strategy
The Vision Centre is designed to bring research and development, clinical expertise, pilot manufacturing, advanced technologies and commercial capabilities under one facility. The hub will support research, clinical studies, product development and new product introduction programs, while enabling greater collaboration across the innovation lifecycle.
CooperVision’s accelerated pipeline development program includes a complete family of 1-day contact lenses for myopia control, a premium 1-day SiHy technology and a next-generation SiHy material for monthly contact lenses. COO is also developing a 1-day SiHy product aimed at expanding fits, a 1-day SiHy toric multifocal lens and a new toric 1-day lens experience for patients with astigmatism.
The Vision Centre builds on CooperVision’s expertise in silicon hydrogel materials, toric and multifocal designs and myopia control. The company’s products currently reach more than 40 million people worldwide. The facility will also use digital tools, data science, analytics and emerging AI-enabled capabilities to improve product development and accelerate the transition from scientific insights to commercial solutions.
The investment comes as The Cooper Companies continues to focus on CooperVision’s commercial execution, operational excellence and innovation. The company expects to provide further updates on its product pipeline going forward and remains focused on opportunities to enhance revenue growth, expand profitability and increase shareholder value.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global soft contact lenses market is estimated to reach $11.3 billion in 2026 and is projected to witness a CAGR of 8.1% through 2030.
Factors such as the rising prevalence of vision-related disorders, including myopia, presbyopia and astigmatism, increasing preference for daily disposable lenses, advancements in silicone hydrogel materials and growing demand for comfortable and convenient vision-correction options are supporting market growth.
The Cooper Companies, Inc. Price
The Cooper Companies, Inc. price | The Cooper Companies, Inc. Quote
COO’s Zacks Rank & Key Picks
The Cooper Companies currently carries a Zacks Rank #5 (Strong Sell).
Some better-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.